Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DINOMITE: Papaverine in Combination With Radiation for Locally Advanced Rectal Cancer
NCT06834126Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Apr 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of papaverine in rectal cancer (2 cohorts), sponsored by City of Hope. Primary endpoints: Acute dose limiting toxicity at 4 weeks, Late dose limiting toxicity at 12 months and 2 more. Started Apr 2025; status: recruiting.
02
Drugs
papaverine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06834126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06834126.